Archive: January 2022

Update on Pure Red Cell Aplasia: Etiology, Diagnosis, and Treatment

H&O What is the definition of pure red cell aplasia (PRCA)? RM PRCA is a normochromic, normocytic anemia that is associated with an extremely low reticulocyte […]

Neoadjuvant Therapy for Melanoma: New and Evolving Concepts

Abstract: Effective systemic therapies, including targeted BRAF/MEK inhibition and immune checkpoint blockade, have significantly changed the treatment landscape for malignant melanoma. Specifically, there have been promising […]

Changing Paradigms in the Treatment of Acute Myeloid Leukemia in Older Patients

Abstract: Standard therapy for acute myeloid leukemia (AML) has long consisted of intensive chemotherapy followed by allogeneic hematopoietic stem cell transplant. Older individuals (≥60 years), who […]

The Next Targets for Small Cell Lung Cancer

H&O  What are the goals of treatment in small cell lung cancer (SCLC)? RS  Our ultimate goal is cure, but we know that SCLC is a […]

Recent Data for Acalabrutinib in Chronic Lymphocytic Leukemia

H&O  What type of drug is acalabrutinib? PG  Acalabrutinib (Calquence, AstraZeneca) is a so-called next-generation Bruton’s tyrosine kinase (BTK) inhibitor. The first-generation BTK inhibitor, ibrutinib (Imbruvica, […]

Letter From the Founding Editor: Twenty Years In: The Long Goodbye

Some cause happiness wherever they go; others whenever they go. —Anonymous; often misattributed to Oscar Wilde What shall I get for Steve and Paul, the publishers of […]

Back to Archive